
From the Editor: Terms and Conditions
The recent report that pharmaceutical company uniQure’s data from its Phase I/II studies provide insufficient evidence for the approval of its investigational gene therapy drug for Huntington’s disease (HD) are a major blow for patients. Huntington’s disease is a rare genetic disorder that can affect around 5-10 people per… Read More










